Live Breaking News & Updates on Oncology Bethanien

Stay updated with breaking news from Oncology bethanien. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Kadcyla Is the 'First Therapy to Show Improved Survival' in a Breast Cancer Subset

Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing neoadjuvant therapy. ....

San Antonio , United States , Neu Isenburg , Centre For Haematology , Goethe University , German Breast Group , Sibylle Loibl , Oncology Bethanien , Antonio Breast Cancer , San Antonio Breast Cancer Symposium , Breast Cancer ,

Adjuvant T-DM1 Provides Sustained Survival Benefit in HER2+ Early Breast Cancer

Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial. ....

San Antonio , United States , Neu Isenburg , Centre For Haematology , German Breast Group , Goethe University , Antonio Breast Cancer , Sibylle Loibl , Oncology Bethanien , San Antonio Breast Cancer Symposium , Hr Positive , Er2 Negative Early Stage Breast Cancer , Adjuvantt Dm1 , Ct01772472 ,